Promising New Weight-Loss Pill From South Korea’s Sam Chun Dang Pharm Mints Country’s Newest Billionaire [Forbes]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Forbes
Sankyo, fueled a rally in the Korean company's shares making chairman Yoon Dae-in a billionaire. getty I nvestor optimism about the pill version of weight-loss injectables being developed by Sam Chun Dang Pharm (SCD) in South Korea has fueled a rally in its shares, which are up by more than 75% so far this month. The stock surge has propelled Yoon Dae-in, the company's chairman, into the billionaire ranks. Yoon, who turns 76 in March, directly and indirectly owns 34% of the company's shares. He also has a small stake in OPTUS Pharmaceutical, the eye-drop manufacturing arm of SCD. Forbes estimates Yoon's net worth at $2.1 billion. Based in Hyangnam, south of Seoul, SCD develops active pharmaceutical ingredients used in treatments for dry-eye disease and high blood pressure. The company also develops novel drug delivery systems, such as S-Pass, which turns injectable medicines into easy-to-take pills. On Thursday, SCD announced that it had signed an agreement with Japanese d
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Astra wins FDA priority review for Daiichi's Datroway; denied approval for lupus therapy [Seeking Alpha]Seeking Alpha
- DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for ImmunotherapyBusiness Wire
- Banking on the long-term potential of oncology drugs: Daiichi Sankyo CFO [CNBC]CNBC
- Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe [Yahoo! Finance]Yahoo! Finance
- Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center EuropeBusiness Wire